# | Title | Journal | Year | Citations |
---|
1 | Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy | Npj Breast Cancer | 2016 | 356 |
2 | MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | Npj Breast Cancer | 2019 | 352 |
3 | Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer | Npj Breast Cancer | 2021 | 331 |
4 | Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set | Npj Breast Cancer | 2016 | 266 |
5 | Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype | Npj Breast Cancer | 2018 | 193 |
6 | Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies | Npj Breast Cancer | 2020 | 181 |
7 | The WISDOM Study: breaking the deadlock in the breast cancer screening debate | Npj Breast Cancer | 2017 | 179 |
8 | Migrating the SNP array-based homologous recombination deficiency measures to next generation sequencing data of breast cancer | Npj Breast Cancer | 2018 | 163 |
9 | The epidemiology, radiology and biological characteristics of interval breast cancers in population mammography screening | Npj Breast Cancer | 2017 | 137 |
10 | If we build it they will come: targeting the immune response to breast cancer | Npj Breast Cancer | 2019 | 132 |
11 | Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants | Npj Breast Cancer | 2016 | 127 |
12 | Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study | Npj Breast Cancer | 2016 | 125 |
13 | HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now | Npj Breast Cancer | 2021 | 123 |
14 | Integrated radiomic framework for breast cancer and tumor biology using advanced machine learning and multiparametric MRI | Npj Breast Cancer | 2017 | 121 |
15 | Inflammatory breast cancer: a model for investigating cluster-based dissemination | Npj Breast Cancer | 2017 | 117 |
16 | Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity | Npj Breast Cancer | 2017 | 115 |
17 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group | Npj Breast Cancer | 2021 | 112 |
18 | Triple negative breast cancer: Pitfalls and progress | Npj Breast Cancer | 2022 | 110 |
19 | Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration | Npj Breast Cancer | 2016 | 109 |
20 | The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk | Npj Breast Cancer | 2017 | 108 |
21 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | Npj Breast Cancer | 2020 | 106 |
22 | Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond | Npj Breast Cancer | 2020 | 106 |
23 | Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer | Npj Breast Cancer | 2018 | 95 |
24 | Evolution of HER2-low expression from primary to recurrent breast cancer | Npj Breast Cancer | 2021 | 94 |
25 | Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy | Npj Breast Cancer | 2017 | 91 |
26 | Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group | Npj Breast Cancer | 2020 | 90 |
27 | Are all cyclin-dependent kinases 4/6 inhibitors created equal? | Npj Breast Cancer | 2019 | 85 |
28 | Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design | Npj Breast Cancer | 2017 | 84 |
29 | E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer | Npj Breast Cancer | 2018 | 84 |
30 | PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) | Npj Breast Cancer | 2016 | 80 |
31 | Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis | Npj Breast Cancer | 2018 | 79 |
32 | Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer | Npj Breast Cancer | 2018 | 78 |
33 | Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT–tamoxifen hybrid therapy | Npj Breast Cancer | 2019 | 78 |
34 | Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion | Npj Breast Cancer | 2017 | 74 |
35 | Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics | Npj Breast Cancer | 2019 | 73 |
36 | Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry | Npj Breast Cancer | 2017 | 69 |
37 | Immunotherapy for early triple negative breast cancer: research agenda for the next decade | Npj Breast Cancer | 2022 | 67 |
38 | 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer | Npj Breast Cancer | 2018 | 65 |
39 | Activin-A signaling promotes epithelial–mesenchymal transition, invasion, and metastatic growth of breast cancer | Npj Breast Cancer | 2015 | 64 |
40 | DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial | Npj Breast Cancer | 2017 | 64 |
41 | Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast | Npj Breast Cancer | 2017 | 63 |
42 | Immunotherapy in breast cancer: an overview of current strategies and perspectives | Npj Breast Cancer | 2023 | 63 |
43 | Connected-UNets: a deep learning architecture for breast mass segmentation | Npj Breast Cancer | 2021 | 61 |
44 | Dramatic response of metaplastic breast cancer to chemo-immunotherapy | Npj Breast Cancer | 2017 | 60 |
45 | Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer | Npj Breast Cancer | 2017 | 59 |
46 | Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry | Npj Breast Cancer | 2017 | 57 |
47 | ARe we there yet? Understanding androgen receptor signaling in breast cancer | Npj Breast Cancer | 2020 | 57 |
48 | Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12 | Npj Breast Cancer | 2017 | 56 |
49 | Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer | Npj Breast Cancer | 2019 | 55 |
50 | PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer? | Npj Breast Cancer | 2019 | 55 |